CSL International Revenue and Competitors
Estimated Revenue & Valuation
- CSL International's estimated annual revenue is currently $36.4M per year.
- CSL International's estimated revenue per employee is $328,000
Employee Data
- CSL International has 111 Employees.
- CSL International grew their employee count by -9% last year.
CSL International's People
Name | Title | Email/Phone |
---|
CSL International Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $52.7M | 146 | 24% | N/A | N/A |
#2 | $61M | 169 | 8% | N/A | N/A |
#3 | $51.2M | 142 | 4% | N/A | N/A |
#4 | $70.4M | 195 | 2% | N/A | N/A |
#5 | $0.2M | 5 | -83% | $22.7M | N/A |
#6 | $350.8M | 764 | 2% | N/A | N/A |
#7 | $34.1M | 104 | 22% | N/A | N/A |
#8 | $98.5M | 273 | 10% | N/A | N/A |
#9 | $37.4M | 114 | 5% | N/A | N/A |
#10 | $32.5M | 99 | 5% | N/A | N/A |
What Is CSL International?
Learn about working at CSL International. Join LinkedIn today for free. See who you know at CSL International, leverage your professional network, and get hired.
keywords:N/AN/A
Total Funding
111
Number of Employees
$36.4M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CSL International News
2022-04-19 - Fibrinogen Concentrates Market Size, Scope And Forecast ...
CSL Behring, Baxter International Inc., LFB Group, ProFibrix BV, Shanghai RAAS, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering,...
2022-04-17 - CSL launches Dualcom Pro 2 variants
CSL has launched its latest variants to its EN54-certified fire range ... or visit CSL's stand (IF3820) at IFSEC International to speak to a...
2022-03-30 - Nashville's fairgrounds racetrack renovation in holding pattern
Cooper's administration said last year that if the report from consultant CSL International now known as CSL Americas "confirms the...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $28.1M | 111 | N/A | N/A |
#2 | $24.4M | 111 | 11% | N/A |
#3 | $17.2M | 111 | -15% | N/A |
#4 | $30M | 111 | -11% | N/A |
#5 | $15M | 111 | 9% | N/A |